Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN).

ORIGIN 3 follows the long-term results from the ORIGIN Phase 2b trial, which demonstrated sustained and substantial reductions in Gd-IgA1, hematuria, and proteinuria and showed stabilized kidney function through 96 weeks.

The company anticipates the 36-week primary efficacy endpoint data from the trial this quarter, which supports planned Biologics License Application (BLA) for accelerated approval to the U.S. FDA in the second half of 2025.

Also Read: Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Pending the submission and FDA review of the BLA, the company said it looks forward to a potential PDUFA date and commercial launch in 2026.

The ORIGIN 3 trial is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of atacicept in patients with IgAN who have persistent proteinuria and remain at high risk of disease progression.

Participants are randomized 1:1 to at-home self-administered once-weekly subcutaneous injections of atacicept 150 mg or placebo for a 104-week double-blind period, followed by a 52-week open-label extension.

The primary efficacy endpoint is the change in proteinuria as evaluated by urine protein to creatinine ratio (UPCR) through 36 weeks in an interim analysis of at least 200 participants.

The key secondary efficacy endpoint is a change in kidney function measured by estimated glomerular filtration rate (eGFR) through 104 weeks in the full study population.

In addition, the company is currently conducting the ORIGIN Extend trial, which provides extended access to atacicept for participants from the ORIGIN Phase 2b or Phase 3 trials until commercial availability in their region and captures longer-term safety and efficacy data.

Vera Therapeutics Stock Prediction For 2025

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Vera Therapeutics, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Vera Therapeutics, the 200-day moving average sits at $37.56, according to Benzinga Pro, which is above the current price of $19.45. For more on charts and trend lines, see a description here.

Story Continues

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

Price Action: VERA stock is up 14.60% at $21.62 at the last check Wednesday.

Read Next:

Teledyne Secures $74.2M US Army Contract To Enhance Sensor Tech

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View Comments